BSPM [Biostar Pharmaceuticals,] 10-Q: (Original Filing)
[FORM 10-Q (Mark One) x March 31, 2010 For the quarterly period ended: Or For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, Maryland 20-8747899 (State or other jurisdiction oforporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province Peoples Republic of China] [ASSETS ACQUISITIONREEMENT Party A:Shaanxi Biostar Biotech, Legal Representative:WANG Ronghua Party B: Xian Meipude Bio-Technology Legal Representative:SUN Yaomei On March 28, 2010, Party A and Party Bain entered into the followingreementncerning Party acquisition of Party Bssets. A. Party Brees to transferl of the technologies andsets of Xian Meipude Bio-Technology to Party A, and Party Arees to] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [CERTIFICATION I, Elaine Zhao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Ronghua Wang Chief Executive Officer ex32-1.htm 5 EX-32.1] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Elaine Zhao Chief Financial Officer (Principal Financial and Accounting Officer) ex32-2.htm 6 EX-32.2]